Finally, to evaluate if the treatment with monoclonal antibodies, which improved the clinical psoriasis features measured by PASI score reduction, affects the different components evaluated (barrier, microbiota, and CD4 cell infiltrate), we evaluated these components in patients treated with the monoclonal antibody anti-IL17 (Secukinumab) or anti-TNF-α (Infliximab or Adalimumab). The gene discussed is IL17A; the disease is psoriasis.